Paper Details

  1. Home
  2. Paper Details

[Randomised phase II study evaluating oral combination chemotherapy (CCNU, cyclophosphamide, etoposide) and intravenous chemotherapy as second-line treatment for relapsed small cell bronchial carcinoma (Trial GFPC0501)].

Author: , ChouaidC, GervaisR, Le CaerH, Le GuenY, PaillotinD

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This phase II randomised trial will compare oral multi drug chemotherapy (CCNU, cyclophosphamide, etoposide) and classical intravenous chemotherapy with cyclophosphamide, doxorubicin and vincristine (CAV) in patients with progressive SCLC after first-line platinum based chemotherapy.
Paper Details　
Original Abstract of the Article :
BACKGROUND: There is no standard second-line treatment for small cell lung cancer (SCLC). The prognosis of these patients is poor and special attention should be paid to both quality of life and economic factors. METHODS: The aim of this phase II randomised trial (GFPC0501) is to compare, in patien...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0761-8425(07)91136-5

データ提供：米国国立医学図書館（NLM）

Second-Line Treatment for Small Cell Lung Cancer: A Desert Oasis of Hope

The fight against small cell lung cancer (SCLC) is a challenging journey, often requiring multiple lines of treatment. This research investigates the efficacy of two different chemotherapy regimens as second-line treatment for patients with relapsed SCLC, seeking to identify the most effective and tolerable approach.

A New Desert Oasis for Relapsed SCLC

The study aims to compare the efficacy and tolerability of two chemotherapy regimens in patients with relapsed SCLC. The researchers will evaluate both the traditional intravenous chemotherapy (CAV) and a novel oral multi-drug chemotherapy regimen. This study holds the potential to provide valuable insights into the optimal treatment strategies for patients with relapsed SCLC.

Improving Treatment for SCLC: Navigating the Desert of Relapse

This research offers hope for patients with relapsed SCLC, a difficult-to-treat condition. By evaluating different chemotherapy regimens, the researchers hope to identify the most effective and tolerable approach for managing this challenging disease, improving patient outcomes and quality of life.

Dr.Camel's Conclusion

This research highlights the ongoing efforts to find better treatment options for patients with relapsed SCLC. Like a camel searching for a refreshing oasis in the unforgiving desert, researchers are constantly striving to discover new therapies that can offer a lifeline for patients battling this challenging disease.

Date :
  1. Date Completed 2007-08-09
  2. Date Revised 2019-10-26
Further Info :

Pubmed ID

17519820

DOI: Digital Object Identifier

10.1016/s0761-8425(07)91136-5

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.